3D bioprinting approaches the clinic: from technological promise to workable application

3D bioprinting is evolving rapidly from experimental lab technology into a serious candidate for clinical and industrial applications. During the WoTS seminar Bioprinting: From Research to Clinical and Industrial Translation It becomes clear where the field stands now: precisely at the tipping point between fundamental research and practical application.

Jutta Wirth PhD, lecturer at Wageningen University & Research with expertise in molecular diagnostics and cell culture, emphasizes that the challenge is no longer primarily technological. “The foundation has been laid: processes, methods, and prototypes exist. The real bottleneck lies in the translation to clinical application.” She is giving the seminar for WoTS 2026. Bioprinting form. She talks enthusiastically about her field, the potential applications of bioprinting, and of course about 'her' seminar.

From proof-of-concept to functional tissue

Bioprinting makes it possible to process living cells and biomaterials, known as bio-inks, layer by layer into three-dimensional structures. Unlike traditional tissue engineering, where separate components such as scaffolds and growth factors are often combined, bioprinting offers precise spatial control over tissue construction.[1]

This controlled construction is essential: it makes it possible to realize complex geometries that closely resemble natural tissue. This opens up prospects for applications such as patient-specific implants, but also for advanced test models for drug development.

In practice, this means that cells derived from the patient themselves, for example from a biopsy, can be used to create tissue structures and test them outside the body. The next step is more ambitious: actually replacing damaged tissue with bioprinted structures that integrate into the body.

Jutta emphasizes that important milestones have already been reached here. “3D printing technologies could solve the shortage of donor organs for organ transplantation in the future. A major breakthrough in the application of 3D bioprinting came with the successful production of functional islets of Langerhans for the treatment of type 1 diabetes.”.[2]

Technological maturity, biological complexity

Although printing technology itself is rapidly maturing, with techniques such as inkjet, extrusion, and laser-based bioprinting, the complexity is shifting to the biological domain.[3]

One of the greatest challenges is creating functional tissue that behaves like natural tissue. Vascularization plays a key role in this: without integrated blood vessels, cells receive insufficient oxygen and nutrients, which severely limits the viability of larger structures.[4]

In addition, the development of suitable bio-inks remains complex. These materials must not only be printable but also possess the right mechanical properties and provide an environment in which cells can survive and differentiate.

Fragmentation hinders breakthrough

According to Jutta, the breakthrough of bioprinting is also being hampered by fragmentation in the field. Research groups often work on separate applications, from cartilage to skin and bone, without these innovations being sufficiently integrated.

It is precisely this integration that is necessary to arrive at clinically usable solutions. Bioprinting is at the intersection of biology, materials science, and engineering, and therefore requires intensive collaboration between disciplines.[5]

The WoTS seminar explicitly positions itself as a platform to break through this fragmentation by bringing together researchers, industry, and clinical practice.

Clinical reality: regulation and validation

In addition to technical and organizational challenges, regulations constitute a major barrier. Bioprinting combines elements of medical devices, cell therapy, and custom implants, and therefore does not always fit within existing frameworks.

Strict requirements regarding safety, reproducibility, and clinical validation make the route to the patient complex and time-consuming. At the same time, the patient-specific nature of bioprinting makes standardization difficult.

Concrete applications in sight

Despite these challenges, applications are getting closer, says Jutta. “Think of personalized implants that integrate better into the body, or models for drug testing that can replace animal testing. Innovative techniques such as bio-sprays also make it possible to apply cell layers for skin repair or test models.”

In the longer term, Jutta outlines a future in which bioprinters are deployed directly in the operating room and tissue is produced 'on demand' during a procedure.

Europe as an ecosystem

The seminar also focuses on international cooperation and funding, including through European programs such as Horizon Europe. These initiatives are crucial for forming consortia that can bridge the gap between research and application.

The Netherlands plays an active role here, with a strong network of universities, knowledge institutions, and companies working together on the bioprinting ecosystems of the future.

From promise to impact

The conclusion is clear: bioprinting has largely left the promise phase behind, but is in the midst of the transition to impact. The success of the coming years depends less on new technological breakthroughs and all the more on collaboration, standardization, and clinical integration.

This seminar positions itself precisely at that intersection: as a meeting place where science, industry, and healthcare work together on the next step – from innovation to application.

Want to know more? Register for WoTS 2026 and sign up for the seminar Bioprinting: From Research to Clinical and Industrial Translation.

Register

[1] Frontiers | Current Developments in 3D Bioprinting for Tissue and Organ Regeneration–A Review

[2] Pharmazeutische Zeitung: ESOT-Kongress 2025. https://www.prnewswire. com/news-releases/esot-kongress-2025-wissenschaftler-schaffen-funktiona le-langerhans-inseln-im-3d-druckverfahren-fur-die-behandlung-von-typ 1-diabetes-302490918.html.

[3] Frontiers | Current Developments in 3D Bioprinting for Tissue and Organ Regeneration–A Review

[4] Bioprinted vascular tissue: Assessing functions from cellular, tissue to organ levels – PMC

[5] Frontiers | Current Developments in 3D Bioprinting for Tissue and Organ Regeneration–A Review